AlphaLISA assays to improve the vaccine development process

Area of Science:

• Biotechnology
• Immunology
• Vaccinology

Background:

• Vaccine development relies on in vitro characterization and animal models.
• Traditional immunoassays like ELISA and ELISPOT are used for immunogenicity, potency, and contaminant detection.
• ELISA and ELISPOT have limitations including high sample volume, variability, and limited automation.

Purpose of the Study:

• To introduce AlphaLISA technology as an improved immunoassay platform.
• To highlight the advantages of AlphaLISA over traditional methods in vaccine development.
• To demonstrate the application of AlphaLISA in assessing vaccine potency.

Main Methods:

• Utilized AlphaLISA, a sensitive, non-wash immunoassay platform.
• Compared AlphaLISA performance against traditional methods (ELISA, ELISPOT).
• Presented examples of AlphaLISA application in vaccine potency assessment.

Main Results:

• AlphaLISA technology alleviates drawbacks of traditional immunoassays.
• Demonstrated improved sensitivity and reduced sample consumption with AlphaLISA.
• Showcased enhanced automatability due to the non-wash nature of AlphaLISA.

Conclusions:

• AlphaLISA technology significantly improves biologics and vaccine development processes.
• This non-wash immunoassay platform offers a more efficient and reliable alternative for vaccine potency testing.
• AlphaLISA enables better assessment of vaccine immunogenicity and quality control.